FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977480503> ?p ?o ?g. }

• W2977480503 endingPage "v423" @default.
• W2977480503 startingPage "v423" @default.
• W2977480503 abstract "Abstract Background Tumour Microvessel density (MVD) is often used as a surrogate marker for tumoral angiogenic activity. In the randomized phase II neo-adjuvant CHIVA trial, ovarian cancer patients (pts) treated with standard chemotherapy plus Nintedanib (Ni) compared to chemotherapy alone had a reduced rate of complete surgical resection at interval debulking surgery (IDS), worse PFS and OS. To explain these results we assessed the predictive/prognostic value of MVD at baseline and the MVD decrease from baseline to IDS. Methods Paired tumours from baseline and IDS were available from 79/188 randomized pts. A total of 158 virtual slides of immunostained tumor section with anti-CD31 were analysed. MVD was quantified by an image processing on whole tumor section. MVD high level was defined as MVD > 33.5 vessel/mm² which is the highest Youden index on the ROC curve for PFS. The relationship between MVD at baseline and PFS and OS was evaluated using Kaplan-Meier survival estimates. Results Main characteristics of the 79 pts were similar to the overall CHIVA population: mean age (62 years), ECOG performance status = 0 (34%), high-grade serous histology (75%). At baseline, MVD was similar in both arms and was low for 35% and 30% of the pts in the Ni and control arm respectively. The rate of complete resection (CC0) was 56% in the Ni arm versus 70% in the control arm. In the low MVD group median PFS was 13.3 months (95%CI 11 – 22.2) versus 17 months (95%CI 13.7 – 20.5) in the high MVD group (p = 0.85). In the low MVD group, PFS in the Ni and control arm were 12.8 (95%CI 10.7-22.2) and 21.3 months (95%CI 12.5-NA) respectively (p = 0.08). The corresponding PFS in the high MVD group were 18.0 (95%CI 14.4-21.6) vs 14.5 months (95%CI 12.4-22.5) (p = 0.22). No difference was observed for OS. Baseline MVD was not associated with the rate of CC0. There was no significant difference in the decrease of MVD at IDS between the Ni arm (38% of the pts) and the control arm (48%, p = 0.4). Conclusions The negative impact of Nintedanib in patients with low baseline MVD tumours may be one explanation of the poor PFS rate observed in the Nintedanib arm of the CHIVA trial. Clinical trial identification 2011-006288-23. Legal entity responsible for the study ARCAGY-GINECO. Funding Health ministry grants( PHRC). Disclosure C. Blanc-Fournier: Honoraria (self): Roche. N. Raban: Travel / Accommodation / Expenses: Roche. G. Ferron: Honoraria (self): Olympus Europe; Advisory / Consultancy: AstraZeneca; Travel / Accommodation / Expenses: Roche. A. Floquet: Advisory / Consultancy, Travel / Accommodation / Expenses: Tesaro; Advisory / Consultancy: Clovis; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Roche. J. Alexandre: Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self): Ipsen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self): PharmaMar; Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen. C. Louvet: Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Halozyme; Advisory / Consultancy: Servier; Advisory / Consultancy: AstraZeneca. J. Florence: Advisory / Consultancy: Roche; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Tesaro; Advisory / Consultancy, Travel / Accommodation / Expenses: Ipsen; Advisory / Consultancy: Astellas; Advisory / Consultancy: Bayer; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Advisory / Consultancy: Sanofi; Travel / Accommodation / Expenses: Janssen. All other authors have declared no conflicts of interest." @default.
• W2977480503 created "2019-10-10" @default.
• W2977480503 creator A5000635815 @default.
• W2977480503 creator A5002063921 @default.
• W2977480503 creator A5007382851 @default.
• W2977480503 creator A5013979411 @default.
• W2977480503 creator A5026702908 @default.
• W2977480503 creator A5039263778 @default.
• W2977480503 creator A5039713572 @default.
• W2977480503 creator A5042079627 @default.
• W2977480503 creator A5044300677 @default.
• W2977480503 creator A5049294891 @default.
• W2977480503 creator A5057225332 @default.
• W2977480503 creator A5058312403 @default.
• W2977480503 creator A5061796867 @default.
• W2977480503 creator A5063179528 @default.
• W2977480503 creator A5074178269 @default.
• W2977480503 creator A5074368454 @default.
• W2977480503 creator A5079483924 @default.
• W2977480503 creator A5080156241 @default.
• W2977480503 creator A5091487792 @default.
• W2977480503 creator A5091655083 @default.
• W2977480503 date "2019-10-01" @default.
• W2977480503 modified "2023-10-14" @default.
• W2977480503 title "Tumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)" @default.
• W2977480503 doi "https://doi.org/10.1093/annonc/mdz250.044" @default.
• W2977480503 hasPublicationYear "2019" @default.
• W2977480503 type Work @default.
• W2977480503 sameAs 2977480503 @default.
• W2977480503 citedByCount "0" @default.
• W2977480503 crossrefType "journal-article" @default.
• W2977480503 hasAuthorship W2977480503A5000635815 @default.
• W2977480503 hasAuthorship W2977480503A5002063921 @default.
• W2977480503 hasAuthorship W2977480503A5007382851 @default.
• W2977480503 hasAuthorship W2977480503A5013979411 @default.
• W2977480503 hasAuthorship W2977480503A5026702908 @default.
• W2977480503 hasAuthorship W2977480503A5039263778 @default.
• W2977480503 hasAuthorship W2977480503A5039713572 @default.
• W2977480503 hasAuthorship W2977480503A5042079627 @default.
• W2977480503 hasAuthorship W2977480503A5044300677 @default.
• W2977480503 hasAuthorship W2977480503A5049294891 @default.
• W2977480503 hasAuthorship W2977480503A5057225332 @default.
• W2977480503 hasAuthorship W2977480503A5058312403 @default.
• W2977480503 hasAuthorship W2977480503A5061796867 @default.
• W2977480503 hasAuthorship W2977480503A5063179528 @default.
• W2977480503 hasAuthorship W2977480503A5074178269 @default.
• W2977480503 hasAuthorship W2977480503A5074368454 @default.
• W2977480503 hasAuthorship W2977480503A5079483924 @default.
• W2977480503 hasAuthorship W2977480503A5080156241 @default.
• W2977480503 hasAuthorship W2977480503A5091487792 @default.
• W2977480503 hasAuthorship W2977480503A5091655083 @default.
• W2977480503 hasBestOaLocation W29774805031 @default.
• W2977480503 hasConcept C126322002 @default.
• W2977480503 hasConcept C143998085 @default.
• W2977480503 hasConcept C168563851 @default.
• W2977480503 hasConcept C71924100 @default.
• W2977480503 hasConceptScore W2977480503C126322002 @default.
• W2977480503 hasConceptScore W2977480503C143998085 @default.
• W2977480503 hasConceptScore W2977480503C168563851 @default.
• W2977480503 hasConceptScore W2977480503C71924100 @default.
• W2977480503 hasLocation W29774805031 @default.
• W2977480503 hasOpenAccess W2977480503 @default.
• W2977480503 hasPrimaryLocation W29774805031 @default.
• W2977480503 hasRelatedWork W2748952813 @default.
• W2977480503 hasRelatedWork W2891273047 @default.
• W2977480503 hasRelatedWork W2899084033 @default.
• W2977480503 hasRelatedWork W3031052312 @default.
• W2977480503 hasRelatedWork W3032375762 @default.
• W2977480503 hasRelatedWork W3159250744 @default.
• W2977480503 hasRelatedWork W4210361769 @default.
• W2977480503 hasRelatedWork W4256514411 @default.
• W2977480503 hasRelatedWork W4292236216 @default.
• W2977480503 hasRelatedWork W2083697902 @default.
• W2977480503 hasVolume "30" @default.
• W2977480503 isParatext "false" @default.
• W2977480503 isRetracted "false" @default.
• W2977480503 magId "2977480503" @default.
• W2977480503 workType "article" @default.